Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

Delayed Quote. Delayed  - 08/26 10:00:00 pm
172.21 USD   +1.61%
08/08 Amadeus invests in genetic testing pioneers, Igenomix
08/08 ILLUMINA : Personal Genome Diagnostics To Collaborate With Illumina ..
07/28 ILLUMINA : Names Philip W. Schiller to its Board of Directors
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Illumina : Presolicitation Notice - MiSeq Instrument

share with twitter share with LinkedIn share with facebook
share via e-mail
08/26/2016 | 03:34pm CEST

Notice Type: Presolicitation Notice

Posted Date: 25-AUG-16

Office Address: Department of Health and Human Services; Centers for Disease Control and Prevention; Procurement and Grants Office (Atlanta); 2920 Brandywine Road, Room 3000 Atlanta GA 30341-4146

Subject: MiSeq Instrument

Classification Code: J - Maintenance, repair & rebuilding of equipment

Solicitation Number: PR01008

Contact: Michael A. Harwell, Contracting Officer, Phone 7704883224, Email wyu4@cdc.gov

Description: Department of Health and Human Services

Centers for Disease Control and Prevention

Procurement and Grants Office (Atlanta)

The Centers for Disease Control and Prevention, NCIRD/ISD, 1600 Clifton Rd. NE, Mailstop A19, Atlanta, GA, 30333, hereby announces its intent to issue a sole source contract to Illumina, Inc. 5200 Illumina Way, San Diego, CA 92122 to procure a MiSeq instrument for sequencing bacterial genomes. NAICS Code: 334516

Period of Performance: Deliver by 09/30/2016

The statutory authority permitting other than full and open competition is 41 U.S.C. 253(c)(1) as cited in FAR 13.106-1(b)(1)(i). The MiSeq Sequencer has a unique process that is required for the research related to this procurement. The high throughput combined with high accuracy in the data allows CDC to analyze many genomes at one time.

Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 3 days from the posting date of this notice, their written capabilities statement, proposal or quotation which shall be considered by the agency for future procurement. Please forward the capability statement and/or pricing information to Michael Harwell, Contracting Specialist, PR 01008, Centers for Disease Control, Procurement and Grants Office, ATTN: Michael Harwell, MS: K14, 2920 Brandywine Road, Atlanta, GA 30341. All vendors must be registered in the System for Award Management (SAM) prior to an award of a federal contract. The website is: www.sam.gov.

This is a posting of a sole source award to Illumina, Inc. and is not a request for competition.

Link/URL: https://www.fbo.gov/spg/HHS/CDCP/PGOA/PR01008/listing.html

(c) 2013 Federal Information & News Dispatch, Inc., source Federal Documents

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ILLUMINA, INC.
08/26 ILLUMINA : Presolicitation Notice - MiSeq Instrument
08/25 ILLUMINA : Patent Issued for Compositions and Methods for Preparing Oligonucleot..
08/24 ILLUMINA : Combine Solicitation - NextSeq 500 Sequencing System and MiSeq System
08/23 ILLUMINA : Presolicitation Notice - Maintenance Support Services for Illumina Hi..
08/23 ILLUMINA : Amendment to Combined Synopsis/Solicitation - Illumina Minisequencing..
08/23 ILLUMINA : Combine Solicitation - Illumina Minisequencing System
08/23 ILLUMINA : Presolicitation Notice - MiSeq and HiSeq Reagent Kits
08/23 ILLUMINA : Special Notice - Notice of Intent to Award Sole Source Illumina Miseq
08/23 ILLUMINA : Presolicitation Notice - MiSeq Integrated Sequencing System
08/19 ILLUMINA : Presolicitation Notice - 2016 NCI Surgery Branch Genetic Analysis Seq..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
08/17DJAGILENT TECHNOLOGIES : Tech Tapers Annual Outlook Amid Slowing Life Sciences Sal..
08/15DJFisher & Paykel Files Patent Infringement Claim Against ResMed
08/02DJCERNER : Edges Annual Revenue Guidance Lower
07/29DJSony Reports Surprise Profit
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
08/26 COMPANION DIAGNOSTICS (CDX) : More Drugs At A Fraction Of The Cost
08/25 Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2016 Update
08/23 Illumina Deserves Its Valuation
08/22 Illumina - Can GRAIL Deal A Death Blow In The War Against Cancer?
08/18 Thermo Fisher rumored to make $30B bid for Illumina
Financials ($)
Sales 2016 2 483 M
EBIT 2016 704 M
Net income 2016 461 M
Finance 2016 500 M
Yield 2016 -
P/E ratio 2016 55,06
P/E ratio 2017 46,71
EV / Sales 2016 9,97x
EV / Sales 2017 8,66x
Capitalization 25 246 M
More Financials
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 22
Average target price 154 $
Spread / Average Target -10%
Consensus details
EPS Revisions
More Estimates Revisions
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Robert P. Ragusa Senior Vice President-Global Quality & Operations
Marc A. Stapley EVP, Chief Financial & Administrative Officer
Mostafa Ronaghi Chief Technology Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.-10.28%25 246
PHILIPS10.29%27 591
More Results